Related Experiment Videos
[Effect of estradiol dipropionate in various doses on induced uterine sarcomagenesis in mice]
Abstract:
Uterine sarcomas in (CBA X C57B1)F1 mice receiving 1,2-dimethylhydrazine (DMH) developed in 20% of animals. Concomitant administration of estradiol-dipropionate (EP) in doses of 2, 10 and 30 micrograms/mouse significantly increased tumour incidence up to 46.9, 62.5, and 50%, respectively, and shortened their latency: 42.3 weeks in a group receiving DMH alone and 36.7, 38.4 and 30.5 weeks in groups receiving DMH plus 2, 10 or 30 micrograms EP, respectively.
Insights
Estradiol-dipropionate significantly increased uterine sarcoma incidence and shortened tumor latency in mice treated with 1,2-dimethylhydrazine. This highlights a potential hormonal influence on chemical carcinogenesis.
Area of Science:
- Oncology
- Carcinogenesis
- Endocrinology
Background:
- Uterine sarcomas are rare malignancies.
- Chemical carcinogens like 1,2-dimethylhydrazine (DMH) are used to induce tumors in animal models.
- Hormonal factors may influence cancer development.
Purpose of the Study:
- To investigate the effect of estradiol-dipropionate (EP) on the incidence and latency of uterine sarcomas induced by DMH in mice.
Main Methods:
- Female (CBA X C57B1)F1 mice were administered 1,2-dimethylhydrazine (DMH).
- Groups received concomitant administration of varying doses of estradiol-dipropionate (EP) (2, 10, or 30 micrograms/mouse).
- Tumor incidence and latency were recorded.
Main Results:
- DMH alone induced uterine sarcomas in 20% of mice.
- Concomitant EP administration significantly increased tumor incidence: 46.9% (2 µg EP), 62.5% (10 µg EP), and 50% (30 µg EP).
- EP shortened tumor latency compared to DMH alone (42.3 weeks vs. 36.7-30.5 weeks).
Conclusions:
- Estradiol-dipropionate enhances the carcinogenic effect of DMH on the mouse uterus.
- Hormonal stimulation may play a significant role in the development of chemically induced uterine sarcomas.